Oncogenic ARAF mutation in a metastatic lung adenocarcinoma from a patient exhibiting sustained sorafenib response.

被引：0
|
作者：
Greulich, Heidi E. [1 ]
Imielinski, Marcin [1 ]
Kaplan, Bethany [1 ]
Araujo, Luiz [2 ]
Amann, Joseph [2 ]
Horn, Leora [3 ]
Villalona, Miguel [2 ]
Meyerson, Matthew [1 ]
Carbone, David [2 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Ohio State Univ, Columbus, OH 43210 USA
[3] Vanderbilt Univ, Nashville, TN 37235 USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2013年 / 12卷 / 11期
关键词：
D O I：
10.1158/1535-7163.TARG-13-C139
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
C139
引用
收藏
页数：1
相关论文
共 50 条
  • [1] ONCOGENIC ARAF MUTATION IN LUNG ADENOCARCINOMA
    Imielinski, Marcin
    Greulich, Heidi
    Kaplan, Bethany
    Araujo, Luiz
    Amann, Joseph
    Horn, Leora
    Villalona-Calero, Miguel
    Meyerson, Matthew
    Carbone, David P.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S349 - S350
  • [2] Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma
    Imielinski, Marcin
    Greulich, Heidi
    Kaplan, Bethany
    Araujo, Luiz
    Amann, Joseph
    Horn, Leora
    Schiller, Joan
    Villalona-Calero, Miguel A.
    Meyerson, Matthew
    Carbone, David P.
    JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (04): : 1582 - 1586
  • [3] Extraordinary Response to Erlotinib Therapy in a Patient with Lung Adenocarcinoma Exhibiting KRAS Mutation and EGFR Amplification
    Krejci, J.
    Pesek, M.
    Grossmann, P.
    Krejci, M.
    Ricar, J.
    Benesova, L.
    Minarik, M.
    CANCER GENOMICS & PROTEOMICS, 2011, 8 (03) : 135 - 138
  • [4] Sustained Partial Response to Afatinib in a Patient With Lung Adenocarcinoma Harboring HER2V659E Mutation
    Chang, Ling-Kai
    Shih, Jin-Yuan
    JCO PRECISION ONCOLOGY, 2020, 4 : 912 - 915
  • [5] Atypical response to erlotinib in a patient with metastatic lung adenocarcinoma: A case report
    Sakhri L.
    Meynet E.
    Ferrer L.
    Pirvu A.
    Ferretti G.
    Moro-Sibilot D.
    Journal of Medical Case Reports, 8 (1)
  • [6] A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation
    Sereno, Maria
    Moreno, Victor
    Moreno Rubio, Juan
    Gomez-Raposo, Cesar
    Garcia Sanchez, Sagrario
    Hernandez Jusdado, Rebeca
    Falagan, Sandra
    Zambrana Tebar, Francisco
    Casado Saenz, Enrique
    ANTI-CANCER DRUGS, 2015, 26 (09) : 1004 - 1007
  • [7] Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation
    Jenkins, Russell W.
    Oxnard, Geoffrey R.
    Elkin, Sheryl
    Sullivan, E. Kelly
    Carter, Jennifer L.
    Barbie, David A.
    CLINICAL LUNG CANCER, 2015, 16 (05) : E101 - E104
  • [8] A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an EGFR-KDD and Response to Afatinib
    Xu, C.
    Wang, W.
    Zhang, Q.
    Wu, B.
    Zhuang, W.
    Zhu, Y.
    Chen, Y.
    Fang, M.
    Chen, G.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S1032 - S1033
  • [9] A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring anEGFR-KDD and Response to Afatinib
    Chen, Dong
    Li, Xing-liang
    Wu, Biao
    Zheng, Xiao-bin
    Wang, Wen-xian
    Chen, Hua-fei
    Dong, Yi-yu
    Xu, Chun-wei
    Fang, Mei-yu
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [10] Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium
    Steuer, Conor E.
    Behera, Madhusmita
    Berry, Lynne
    Kim, Sungjin
    Rossi, Michael
    Sica, Gabriel
    Owonikoko, Taofeek K.
    Johnson, Bruce E.
    Kris, Mark G.
    Bunn, Paul A.
    Khuri, Fadlo R.
    Garon, Edward B.
    Ramalingam, Suresh S.
    CANCER, 2016, 122 (05) : 766 - 772
12345